Lixte Biotechnology Enters the cryptocurrency space: Strategic move or speculative gambling?

Against the backdrop of growing trends in blockchain integration in biotech fields such as DeSci and supply chain management, LIXTE Biotech Holdings allocates up to 25% of its funds to cryptocurrencies such as Bitcoin as a long-term hedging tool and potential value driver. The move comes after the company recently raised $6.5 million to diversify its assets, but there is also a risk of volatility for a company focused on oncology research and development.